Generic ConZip Availability
CONZIP (tramadol hydrochloride - capsule, extended release;oral)
Manufacturer: CIPHER PHARMS INC
Approval date: May 7, 2010
Strength(s): 100MG [RLD], 200MG, 300MG
Manufacturer: CIPHER PHARMS INC
Approval date: August 1, 2011
Has a generic version of ConZip been approved?
No. There is currently no therapeutically equivalent version of ConZip available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of ConZip. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Extended release composition containing Tramadol
Issued: December 28, 2010
Inventor(s): Deboeck; Arthur M. & Vanderbist; Francis & Sereno; Antonio
Assignee(s): Galephar Pharmaceutical Research, Inc.
An oral Tramadol-containing pharmaceutical composition suitable for once daily administration, which contains an amount of Tramadol or a pharmaceutically acceptable salt thereof, providing in vivo, a time of Tramadol peak plasma concentration (Tmax) of greater than 10 hours, and peak Tramadol plasma concentration (Cmax) which are less than three times the plasma concentration obtained 24 hours after administration (C24h) of a single dose of the composition.Patent expiration dates:
- April 11, 2022✓✓
- April 11, 2022
- ConZip extended-release capsules Consumer Information (Wolters Kluwer)
- ConZip Consumer Information (Cerner Multum)
- ConZip Advanced Consumer Information (Micromedex®)
- Tramadol Consumer Information (Drugs.com)
- Tramadol Consumer Information (Wolters Kluwer)
- Tramadol extended-release capsules Consumer Information (Wolters Kluwer)
- Tramadol extended-release tablets Consumer Information (Wolters Kluwer)
- Tramadol orally disintegrating tablets Consumer Information (Wolters Kluwer)
- Tramadol Consumer Information (Cerner Multum)
- FusePaq Synapryn Advanced Consumer Information (Micromedex®)
- Tramadol Advanced Consumer Information (Micromedex®)
- Tramadol Hydrochloride AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|